Brief: Aptose Doses First CLL Patient In Phase 1 Study Of CG-806 And Doses Third Cohort In Phase 1 Study Of APTO-253
16/07/2019 12:51
July 16 (Reuters) - Aptose Biosciences Inc APS.TO :
* APTOSE DOSES FIRST CLL PATIENT IN PHASE 1 STUDY OF CG-806
AND
DOSES THIRD COHORT IN PHASE 1 STUDY OF APTO-253
Source text for Eikon: ID:nGNX86LlM3
Further company coverage: APS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aptose Biosciences
See all newsBrief: Aptose Biosciences Says Closing Of Arrangement With Hanmi Pharmaceutical Further Delayed
Brief: Aptose Reports First Quarter 2026 Results
Brief: Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan Of Arrangement
Brief: Leading Independent Proxy Advisory Firm Iss Recommends Aptose Biosciences Shareholders Vote “For” Proposed Plan Of Arrangement With Hanmi Pharmaceutical
Brief: Aptose Biosciences Announces Amendment To Arrangement Agreement And Details Of Shareholders Meeting